Samsung Bioepis has launched its biosimilar etanercept, SB4, in Brazil. The biosimilar, which is being sold as Brenzys, was approved in Brazil in 2017 to treat rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, and nonradiographic axial spondyloarthritis.
Samsung Bioepis has launched its biosimilar etanercept, SB4, in Brazil. The biosimilar, which is being sold as Brenzys, was approved in Brazil in 2017 to treat rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, and nonradiographic axial spondyloarthritis.
The biosimilar is being supplied to the country’s public health system through a partnership between Samsung Bioepis and local partner organizations Bionovis and Bio-Manguinhos/Fiocruz. Under the partnership, Samsung Bioepis will supply the product for sale to the health system for 10 years, during which it will also provide a technology transfer in order to eventually transition manufacturing responsibilities to local facilities in Brazil.
The arrangement is part of a program, known as the Partnership for Productive Development, that brings together government and the private sector to develop strategic products of interest to the Brazilian health system. The program, first introduced in Brazil in 2008, aims to expand access to medicine while providing companies guaranteed purchases of their drug products by the national healthcare system, which provides care to approximately 75% of the nation’s population.
“We are excited to provide our high-quality biosimilars to patients across Brazil, and look forward to working with our local partners to enhance patient access to high-quality healthcare. Equally important, by sharing our scientific knowledge with our local partners, we hope to do our part in contributing to the long-term development of the Brazilian biopharmaceutical industry,” Sang-Jin Pak, senior vice president and head of commercial division, Samsung Bioepis, said in a statement announcing the biosimilar’s launch.
The biosimilar etanercept is also approved in the United States (under the name Eticovo) and in multiple other territories (under the Brenzys brand as well as under the name Benepali). While the etanercept biosimilar is widely used in regions such as the European Union, no launch date for the product has been announced for the US marketplace, and concerns linger about when the product will be able to reach US patients; a recent decision in a long-running legal battle related to the reference etanercept (Enbrel) and a different biosimilar (Sandoz’s Erelzi) upheld the validity of 2 patents on Enbrel that will not expire in the United States until 2028 and 2029, respectively.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.